venetoclax
abbvie,roche
['venetoclax', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)']
amazing oral presentation at #ash22 by on the lack of impact of splicing factor gene mutations in aml. no impact of these mutations when venetoclax-based regimens are used. important to have separate risk stratification guidelines when ven-based regimens are used. 
Assistant Professor, Department of Leukemia, MD Anderson Cancer Center - Research interest: phase I/II clinical trials in AML and ALL, developing new MRD assays